AbdulraheemYacoubMD
Hematology • Westwood, KSMyeloproliferative Disorder Hematology-Oncology
Assistant Professor, Internal Medicine, University Kansas School of Medicine
Dr. Yacoub is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205Phone+1 913-588-6029Fax+1 913-588-3867
Education & Training
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2008 - 2011
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 2005 - 2008
University of Jordan Faculty of MedicineClass of 2003
Certifications & Licensure
KS State Medical License 2010 - 2025
MO State Medical License 2021 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Publications & Presentations
PubMed
- 26 citationsTargeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemiaSiddhartha Ganguly, Trisha Home, Abdulraheem Yacoub, Suman Kambhampati, Huidong Shi
Oncotarget. 2015-09-11 - 1 citationsMomelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.Claire N Harrison, Alessandro M Vannucchi, Christian Recher, Francesco Passamonti, Aaron T Gerds
Advances in Therapy. 2024-09-01 - 65 citationsThe efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-d...Ruben A. Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachee, Mamta Garg
British Journal of Haematology. 2017-01-01
Abstracts/Posters
- Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory MyelofibrosisAbdulraheem Yacoub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center DatabaseAbdulraheem Yacoub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 11...Abdulraheem Yacoub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Pegylated Interferon Leads to High Response Rates in Essential Thrombocythemia and Polycythemia Vera After HydroxyureaOctober 1st, 2019
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
